Continuous Monitoring of Patients in and After the Acute Admission Ward to Optimize Clinical Pathways

August 12, 2026 updated by: Rijnstate Hospital

Hospitals aim to hospitalize patients when necessary and discharge patients when possible. However, the triage process and discharge management of patients in e.g. the Acute Admission Ward, is not a trivial task. The upcoming technology of wearable monitoring devices, whereby patients can be continuously monitored with an unobtrusive vital signs device, might help getting more insight into patients' health condition and thus help facilitate efficient and effective triaging.

Therefore, the primary objective is to assess the effects of continuous monitoring of patients in the acute admission ward (AAW) on the percentage of patients who can be discharged home. Secondary objectives are to assess the length of stay in the acute admission ward and in the in-hospital wards, as well as the effect on admission to the intensive care unit, rapid response team calls and hospital readmission. The predictive value of algorithms applied to the monitoring data combined with other parameters to detect timely deterioration and predict discharge will be assessed. Facilitators and barriers for implementing such a system will be investigated.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

400

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Netherlands
      • Arnhem, Netherlands, 6800 TA
        • Rijnstate Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

In order for a patient to be eligible to participate in this study, the following criteria need to be met:

  • admitted to the AAW
  • Age ≥ 18 years
  • Able to speak and read Dutch
  • Willing and able to provide written informed consent

Exclusion Criteria:

A patient who meets any of the following criteria will be excluded from participation:

  • Not able or willing to wear a wearable sensor on the chest continuously for 14 days
  • Planned major surgery in the upcoming 30 days
  • At the time of AAW admission already known to be discharged home or admitted to the hospital
  • Any skin condition, for example prior rash, discoloration, scars, infection, injury or open wounds at the area (Left lower rib) where the sensor needs to be placed
  • Known sensitivity to medical adhesives
  • Wearing an active implantable device (e.g. ICD, pacemaker)
  • Intend to go to the sauna or go swimming in the upcoming 14 days
  • Pregnant or breastfeeding
  • Use of creams or lotions that are known to influence the skin at the area where sensor is placed (such as medical and non-medical creams or lotions)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Monitoring Group
wearable sensor, besides usual care monitoring
Device: Wearable Sensor
The sensor measures vital signs including heart rate and respiratory rate, posture and level of physical activity.
Other Names:
  • Philips Healthdot
Other: Usual Care
Usual Care Monitoring
Other: Usual Care group
usual care monitoring
Other: Usual Care
Usual Care Monitoring

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of patients discharged home from acute admission ward
Time Frame: up to 7 days
Percentage of patients discharged home from acute admission ward
up to 7 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Length of stay in the acute admission ward
Time Frame: up to 7 days
Length of stay in the acute admission ward
up to 7 days
Length of stay in the in-hospital wards
Time Frame: up to 31 days
Length of stay in the in-hospital wards
up to 31 days
Percentage of Rapid Response Team calls
Time Frame: up to 31 days
Percentage of Rapid Response Team calls
up to 31 days
Percentage of Intensive Care Unit Admissions
Time Frame: up to 31 days
Percentage of Intensive Care Unit Admissions
up to 31 days
Percentage of unplanned readmissions to the hospitals
Time Frame: up to 31 days
Percentage of unplanned readmissions to the hospitals
up to 31 days

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Deterioration
Time Frame: up to 7 days
Deterioration will be assessed using clinical data
up to 7 days
Facilitators and Barriers for implementing continuous monitoring system (interviews)
Time Frame: up to 31 days
Facilitators and Barriers for implementing continuous monitoring system in practice (interviews with stakeholders)
up to 31 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Rijnstate Hospital

Collaborators

University of Twente
Philips Research Eindhoven

Investigators

  • Principal Investigator: Carine JM Doggen, Prof PhD, Rijnstate Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 6, 2021

Primary Completion (Actual)

November 8, 2023

Study Completion (Actual)

November 8, 2023

Study Registration Dates

First Submitted

December 23, 2021

First Submitted That Met QC Criteria

January 5, 2022

First Posted (Actual)

January 6, 2022

Study Record Updates

Last Update Posted (Actual)

August 14, 2026

Last Update Submitted That Met QC Criteria

August 12, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • LHC 2021-1838

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe